IPO-bound PharmEasy buys Thyrocare; is it worth the price and what does this mean for diagnostic sector? – Moneycontrol.com

Several analysts and competitors Moneycontrol spoke to said that the deal would be a win-win for PharmEasy and shareholders of Thyrocare and more importantly for Velumani, the Chairman of Thyrocare, who will be cashing out. Read More